Organigram Global (OGI) said Wednesday it has expanded its investment in Phylos Bioscience through an amended loan and product agreement.

Under the amended agreement, Organigram said it will consolidate its existing investment with a new $3 million advance, bringing the loan principal amount to $10 million. The loan matures on May 25, 2028.

Organigram said that under the agreement, it will receive five-year exclusivity on its chosen autoflower cultivars across Canada, Australia, the UK, Germany, and Israel, with the option to expand further into new markets.